Best Clinical Genomics Companies in China
The 70 best Clinical Genomics companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: 3DMed.
- Mordor Intelligence
- ResearchAndMarkets.com
Ranked: Best Clinical Genomics companies in China
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3DMed Provider of personalized diagnostic treatment solutions for cancer | $365M | 68 mo ago | Series D | 215 | Simon Shung Founder | — | — | — |
| 2 | Genecast Non-invasive diagnosis and monitoring of cancer | $246M | 67 mo ago | Series E | — | Ma Guosheng Co-Founder & VP | — | — | 1 job opening · 1 partnership |
| 3 | Guangzhou Kang Liming Biotechnology Provider of cancer detection kits | $220M | 56 mo ago | Series D | — | Hongzhi Zou Founder and Chairman | — | — | — |
| 4 | Singlera Genomics Developer of the NGS-based platform to detect cancer 72Moat top 21%Funding top 26%Market top 30%Patents top 33% All 6 signals ▾Moattop 21% Fundingtop 26% Markettop 30% Patentstop 33% Innovationtop 41% Globalbottom 40% Moat: Editorial + unicorn rating 8/10 · IP moat: 29 patents Funding: Raised $209M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $209M | 23 mo ago | Series B | 300 | — | — | 29 patents Liquid biopsy DNA methylation biomarkers for cancer detection and tumor assessment | — |
| 5 | Burning Rock Developer of personalised diagnostic and treatment services based on genomic big data analysis | $203M | 88 mo ago | Public | 1,138 | Shannon Chuai Co-Founder | — | 42 patents Cancer genomics diagnostics: tumor risk assessment, mutation and copy-number detection, bioinformatics tools. | — |
| 6 | Zhejiang Nuhui Health Technology Provider of early cancer screening and testing services | $152M | 71 mo ago | Public | 1,041 | Yiyou Chen Co-Founder | — | — | — |
| 7 | Geneseeq Geneseeq is an industry leader in next-generation sequencing (NGS) fully committed to the research and… | $128M | 77 mo ago | Series D | 1,345 | — | WordPressMySQLPHP+19 | — | — |
| 8 | BerryOncology Developer of gene sequencing products for disease diagnostics | $108M | 58 mo ago | Series B | — | Zhou Yi CEO | — | — | — |
| 9 | AnchorDx Developer of high throughput gene sequencing platform for clinical application | $73M | 64 mo ago | Series C | 20 | — | — | — | — |
| 10 | Ustar Biotechnologies Isothermal amplification kits for pathogen detection and genotyping of infectious diseases | $62M | 54 mo ago | Series E | 65 | — | WordPressMySQLPHP+21 | 31 patents Integrated microfluidic nucleic acid detection platforms for rapid CRISPR‑based diagnostics | — |
| 11 | CircleDNA Provider of internet first diagnostics platform for genetic tests | $60M | 69 mo ago | Series B | — | Lawrence Tzang Co-Founder | Cart FunctionalityShopifyAmazon ALB+33 | — | — |
| 12 | Zhuhai Shengmei Biodiagnostic Technology Developer of liquid biopsy-based lung cancer diagnostic technology | $46M | 62 mo ago | Series B | 59 | — | — | — | — |
| 13 | Haplox Provider of ultra sensitive liquid biopsy tests for cancer | $39M | 46 mo ago | Series D | 724 | Fang Wen Co-Founder & COO | Node.jsTailwind CSSVue.js+5 | — | — |
| 14 | Beikang Medical Developer of NGS-based diagnostic solutions for neonatal | $37M | 73 mo ago | Public | 488 | — | — | — | — |
| 15 | Yikon Genomics Provider of NIPT and liquid biopsy tests using next-generation sequencing | $31M | 79 mo ago | Series C | 5,000 | — | Element UIAnimate.cssGSAP+4 | 21 patents Patents concentrated in chemistry & materials | — |
| 16 | Beijing Rubber Xin Biological Technology Developer of tumor genetic testing reagents and instruments | $29M | 41 mo ago | Series B | — | Cao Shanbai CEO | — | — | — |
| 17 | Safford Decoding Provider of genetic analysis and precision medicine services | $26M | 61 mo ago | Series B | 160 | Wei L Founder | — | — | — |
| 18 | Beijing Xinyi Biotechnology Manufacturer of micro-droplet digital PCR and in vitro diagnostic reagents | $23M | 27 mo ago | Series B | — | Wenjun Yang Co-Founder | — | — | — |
| 19 | Aegicare Developer of NGS-based genetic diagnostic devices | $20M | 65 mo ago | Series B | 9 | Yang Li Founder & CEO | — | — | — |
| 20 | Third Wave Technologies Molecular diagnostic test devices and reagents | $19M | 222 mo ago | Acquired | 179 | Kevin Conroy CEO | TurbopackNode.jsPHP+18 | — | — |
| 21 | Polaris Biology Single-cell diagnostic platform for detection of tumors | $18M | 72 mo ago | Series B | — | Yuchong Wang CEO | — | 32 patents Advanced mass spectrometry hardware for single-particle analysis and biomolecule labeling | — |
| 22 | Topgen Provider of gene mapping and detection of tumors | $17M | 71 mo ago | Series C | 141 | — | — | — | — |
| 23 | Berry Genomics Provider of genetic testing products and tests | $16M | 134 mo ago | Public | 1,438 | — | — | 92 patents Non‑invasive prenatal testing and hereditary mutation detection using targeted sequencing kits. | — |
| 24 | GloriousMed Provider of gene testing services for immunodiagnosis and treatment | $16M | 56 mo ago | Series B | — | Jin Ge CEO | — | — | — |
| 25 | Beijing Youxun Medical Laboratory Provider of tests for detecting non-invasive single gene disorders, prenatal testing and tumor detection | $15M | 49 mo ago | Series B | — | Ye Zhou CEO | — | — | — |
| 26 | Jiabao Next-generation sequencing integration services for assisted pregnancy | $14M | 70 mo ago | Series B | — | Feng Tao Co-Founder & CEO | — | 4 patents Air purification systems and related filtration technologies | — |
| 27 | Shenzhen Vienomics Bio Tech Provider of cancer screening technologies based on the gene sequencing technology and bioinformatics analysis | $7M | 91 mo ago | Deadpooled | — | Liu Chaoyu CEO | — | — | — |
| 28 | Quantibio Provider of gene mapping services of the human gut microbiome | $5M | 101 mo ago | Series A | — | Bowen Zhao Founder & CEO | — | — | — |
| 29 | Anpac Developer of novel multi-level and multi-parameter liquid biopsy tests for cancer | $2M | 126 mo ago | Series B | 75 | Herbert Yu Co-Founder | — | — | — |
Top 12 Clinical Genomics companies in China
#1
Series B · Pudong, Shanghai · founded 2014 · 300 employees$208.6Mraised▾
Developer of the NGS-based platform to detect cancer. The company has methylation haplotyping technology for detecting cancer biomarkers. Tumor cells release circulating tumor DNA (ctDNA) into the blood when undergoing apoptosis or necrosis and this ctDNA is detected as cancer biomarkers. The company has developed a PanSeer assay that measures distinct tumor-specific methylation patterns in adjacent methylation sites. It can detect cancer up to four years before conventional diagnosis.
- Jul 2024Series B$13.8M
- Jun 2022Series B$44.9M
- Dec 2020Series B$150M
- 2018Series A—
#2
Series B · Haidian, Beijing · founded 2015$23.2Mraised▾
Beijing Xinyi Biotechnology is manufacturing micro-droplet digital PCR and in vitro diagnostic reagents. Products include drop maker sample preparation, chip reader, PCR universal amplification reagent, genetic testing kit (for scientific research only), micro-droplet detection oil, nucleic acid extraction reagent (magnetic beads method), etc.
- Feb 2024Series B—
- Jan 2021Series B$23.2M
- Sep 2018Seed—
#3
Series D · Guangzhou, Guangdong · founded 2015$219.7Mraised▾
Guangzhou Kang Liming Biotechnology provides cancer detection kits. Chang'an Heart, the company's platform product, is a fecal DNA colon cancer detection kit. The kit is meant for keeping the sample intact until it reaches the laboratory. The company also provides screening services for lung, gastric, and bladder cancer.
- Oct 2021Series D$87M
- Sep 2020Series C$88M
- Apr 2019Series B$44.7M
- Series A—
#4
Series E · Wuxi, Jiangsu · founded 2014$246Mraised▾
Genecast develops solutions for non-invasive diagnosis and monitoring of cancer. Its assays detect circulating tumor DNA to detect cancer mutations and monitor tumor evolution. Physicians can use these results to tailor and modify treatments for patients according to their specific tumor profile. The company claims that its product is being used in 200 hospitals in China and abroad, including UPenn.
- Oct 2020Series E$149.2M
- Oct 2019Series D$42.4M
- Feb 2018Series C$33.4M
- Feb 2017Series B$18M
#5
Series D · Shanghai, Shanghai · founded 2010 · 215 employees$365.1Mraised▾
Provider of personalized diagnostic treatment solutions for cancer. The company depends on an individual's genetic information for the production of precision medicine. The company sequences the genetic makeup of a patient to develop a personalized treatment. The company has different sets of gene profiles for detecting the mutation in genes that can lead to solid tumors or malignancy. The company has developed products for cancer detection, including histology genomic tests, ctDNA liquid biopsies, and exosome liquid biopsies.
- Oct 2020Series D$223.6M
- Oct 2020Series C—
- Jan 2020Series C$40.2M
- Nov 2017Series C$101.2M
#6
Series B · Haidian, Beijing · founded 2017$28.7Mraised▾
Developer of tumor genetic testing reagents and instruments. It has developed AcornSTAS for solid tumor mutations, AcornHMAS for hematological tumor mutations, AcornSTDB which is a solid tumor gene knowledge database and others.
- Dec 2022Series B$28.7M
- Apr 2020Series A—
#7
Public · Beijing, Beijing · founded 2013 · 1041 employees$151.8Mraised▾
Provider of early cancer screening and testing services. The company has developed a fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. The company also has a product for gastric cancer detection through their Helicobacter pylori toxicity factor detection technology. The company leverages its expertise in genetic testing, molecular diagnostics, and large data platforms and software in developing early detection tests for cancer.
- Jul 2020Series E$30M
- Apr 2020Series D$20M
- May 2019Series C$66M
- Aug 2017Series B$20M
#8
Series D · Shenzhen, Guangdong Province · founded 2014 · 724 employees$39.5Mraised▾
Provider of ultra-sensitive liquid biopsy tests for cancer. Its flagship CUBE-ctDNA sequencing technology enables easy detection of circulating tumor cells. The company has panels for lung, breast, and GI cancers, in addition to a pan-cancer panel. In addition, it also has a panel for the detection of cardiovascular risk.
- Jul 2022Series D—
- Jun 2018Series B—
- Dec 2017Series A$32M
- May 2016Series A$7.5M
#9
Series E · Hangzhou, Zhejiang · founded 2005 · 65 employees$61.8Mraised▾
Isothermal amplification kits for pathogen detection and genotyping of infectious diseases. Its proprietary technologies include instrument-free nucleic acid extraction, isothermal amplification, and rapid DNA amplicon detection device which form two nucleic acid testing platforms for microbe detection and SNP/Mutation detection. It developed a series of isothermal amplification testing kits based on these two platforms for pathogen detection and genotyping for tuberculosis, sexually transmitted diseases, and HBV genotyping.
- Nov 2021Series E$47M
- Feb 2021Series E—
- Aug 2014Series B$11.3M
- 2012Series B—
#10
Series B · Fuzhou, Fujian · founded 2017$108.2Mraised▾
Developer of gene sequencing products for disease diagnostics. The company has developed tumor gene diagnosis products that are patented cSMART (gene mutation detection technology) and cSMART2.0 technology (detection of all-exome regions) for tumor precision medicine. The company is also developing technology for liver cancer screening.
- Aug 2021Series B$108.2M
#11
Public · Guangzhou, Guangdong · founded 2014 · 1138 employees$203.3Mraised▾
Developer of personalized diagnostic and treatment services based on genomic big data analysis. It provides next-generation sequencing-based cancer diagnostics, including bioinformatics analysis and tumor molecular pathology, and immunohistochemistry. Uses diagnostic tools to gather the information that enables the personalized treatment of cancer. It also offers liquid biopsy tests for lung cancer.
- Feb 2019Series C$127.5M
- Dec 2016Series B$43.1M
- Aug 2015Series A$23M
- 2014Series A$9.7M
#12
Series C · Guangzhou, Guangdong · founded 2015 · 20 employees$73Mraised▾
Developer of high throughput gene sequencing platform for clinical application. It enables early diagnosis of genetic diseases and thereby intervene and reduce the incidence of the disease. Its proprietary test menu includes non-invasive prenatal testing, pre-implantation carrier screening, cancer diagnostics, and liquid biopsy tests.
- Feb 2021Series C$40M
- Nov 2017Series B$28M
- Dec 2015Series A$5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in China
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 3,336 China-affiliated papers.
- Chinese Academy of Medical Sciences & Peking Union Medical College188
- Peking University172
- Chinese Academy of Sciences160
- Shanghai Jiao Tong University159
- Fudan University140
- Liquid biopsy20→216
- Point-of-care testing24→173
- Point of care14→100
- Cancer12→84
- Detection limit8→71
- Liquid biopsy62→410
- Cancer30→159
- Biomarker14→138
- Biopsy11→129
- Point-of-care testing53→138
- Liquid biopsy17→119
- Cancer9→51
- Biopsy9→42
- Biomarker4→37
- Precision medicine2→33
Where diagnostics is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in China
China diagnostics patent filing is accelerating — 33 filings from 15 assignees (2016–2025), led by Autobio Labtec Instr, Chengdu Illumaxbio TECH, UNIV CITY HONG KONG; annual filings 1→6.
- Autobio Labtec Instr6
- Chengdu Illumaxbio TECH6
- UNIV CITY HONG KONG4
- Phase Scient International4
- Ankon Medical TECH Shanghai3
- Shenzhen Mindray Animal Medical 3
- UNIV Fuzhou1
- Pharus Taiwan1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.